Amneal Says Vertical Integration Will Be Key To Compete In Biosimilars
Chirag Patel Says Firm Is Already Proving Itself Against Rivals Such As Pfizer And Amgen
Stressing the need for vertical integration to be a successful biosimilars developer in the long run, Amneal co-CEO Chirag Patel has set out the firm’s future strategy in the area – including aiming to be quicker to market with future launches – as Amneal proves itself against rival biosimilars players in the US market.
You may also be interested in...
Ahead of revealing its full first-quarter results, Amneal has released limited preliminary details of its financials for the first three months of 2023, pointing to double-digit sales and profit growth in Q1.
Following Amneal’s first biosimilar launch last month, the company has made it two with the introduction of its Releuko version of filgrastim in the US. It plans to complete the trinity with its Fylnetra pegfilgrastim biosimilar early next year.
Fresh from introducing its first biosimilar in the US, Amneal expects two additional biosimilars to launch in the next couple of months as well as several further generics by year end. The firm also has its eye on future biosimilars opportunities where it can be early to market.